Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 proof-of-concept trial of efgartigimod (IV) in chronic inflammatory demyelinating polyneuropathy (CIDP)

Trial Profile

Phase 2 proof-of-concept trial of efgartigimod (IV) in chronic inflammatory demyelinating polyneuropathy (CIDP)

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Efgartigimod (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2018 New trial record
    • 17 Sep 2018 According to argenx media release, company plans to initiate in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top